NERVIANO, 31 October 2022 – Nerviano Medical Sciences Srl (NMS Srl), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that Salvatore Marengoni Galdy, M.D., has joined the Global Clinical Development Team as Global Clinical Lead, effective immediately. Dr. Galdy will drive values of our assets through planning and leading the clinical development to meet all time, quality, budget, Company standards and scientific requirements.

“We are excited to welcome Salvatore to our Global Clinical Development team at this important moment for our company, as several of our co-lead programs enter global clinical trials,” said Lisa Mahnke, M.D., PhD, Board Member and Chief Medical Officer* of NMS Srl and Managing director of Nerviano Medical Sciences Inc., the US subsidiary. “Salvatore brings a breadth of global drug development experience making him an invaluable contributor to the company as we advance our clinical assets for patients currently with limited options.”

Dr. Galdy commented: “My years of being deeply involved in the oncology field gives me the opportunity to understand the urgent need and the importance to deliver new therapeutics. I am honored to work alongside such a patient-focused team and look forward to advance our innovative pipeline together with all our Global Clinical Development colleagues.”

Dr. Galdy joins us from Oncology Clinical Practice at Valle Olona hospital. Prior to that he was with Bayer SpA, Milan, as Clinical Development Leader. He has a range of research and clinical experiences including the European Institute of Oncology in Milan, Bergamo and Parma Hospitals.  He completed Medical Oncology clinical residency at the University of Parma at which he took his medical degree.  He has a long publication history with a variety of treatments and cancer pathways including HER2/HER3, mTOR, RAF, pembrolizumab, ramucirumab, platin, temozolomide, sunitinib and more.  He has published in colorectal, gastric, biliary tract carcinomas and neuroendocrine tumors.

Link:20221031-Global Clinical Lead



 

from NMSGroup